NYSE
$1.65▼ 2.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $24.7MShares out 15.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.9After-hours26.10.10 06:198-KKey event#●●●
Serina Therapeutics, Inc.
Serina Therapeutics filed a Certificate of Elimination with the State of Delaware on October 5, 2026, as all outstanding shares of Series A Convertible Preferred Stock have been converted into common stock. Consequently, the 965,250 shares previously designated as Series A Preferred Stock have reverted to the status of authorized but unissued preferred shares.…more
$1.65-2.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9Pre-market26.09.09 20:438-KKey event
Serina Therapeutics, Inc.
Serina Therapeutics announced that the Independent Safety Monitoring Committee has recommended advancing to Cohort 2 following a blinded review of the Phase 1b registrational study for SER-252 in patients with advanced Parkinson's disease. The study confirmed safety, tolerability, and a pharmacokinetic profile consistent with sustained apomorphine exposure, with topline data from the single-ascending-dose portion expected in the first half of 2027.…more
$1.65-2.08%vs prev closeView filingShare - 9.1Pre-market26.09.01 13:15filedEFFECTOther
Serina Therapeutics, Inc.
The registration statement filed by Serina Therapeutics became effective with the SEC on August 31, 2026. This effectiveness allows the company to officially proceed with the issuance and sale of the securities specified in the filing.…more
$1.65-2.08%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23After-hours26.09.24 05:18#●●●#●●●
Serina Therapeutics to Host CEO Webinar on Parkinson’s Disease Clinical Progress…more
Serina Therapeutics will host a CEO webinar to discuss the clinical progress of its Parkinson’s disease candidate, SER-252. The event provides a platform for management to engage with investors regarding the company's therapeutic developments.…more
$1.65-2.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.10After-hours26.09.11 05:05
●●●●●●●● ●●●●● ●●●●●●
Serina Therapeutics announced that its CEO will present at the H.C. Wainwright 28th Annual Global Investment Conference. The company will also conduct one-on-one meetings with investors to discuss its clinical-stage pipeline.…more
$1.65-2.08%vs prev close - 9.9Pre-market26.09.09 20:45
●●●●●●●● ●●●●● ●●●●●●
Serina Therapeutics has advanced to the second cohort of its Phase 1b study for SER-252 after confirming safety and tolerability in the initial group. While early observations are encouraging, the study remains in the preliminary stages with further data expected in 2027.…more
$1.65-2.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report